Here, our data indicates VTE’s inhibition of LXRα activity may require AMPK activation and AMPK-LXRα signaling activation may be VTE’s underlying mechanism against NASH. The gene discussed is NR1H3; the disease is metabolic dysfunction-associated steatohepatitis.